Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Outcome Measures in Clinical Trials for Multiple Sclerosis.

van Munster CE, Uitdehaag BM.

CNS Drugs. 2017 Mar;31(3):217-236. doi: 10.1007/s40263-017-0412-5. Review.

2.

Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab.

Dubey D, Cano CA, Stuve O.

Neuropsychiatr Dis Treat. 2015 Sep 18;11:2405-14. doi: 10.2147/NDT.S90473. eCollection 2015. Review.

3.

Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.

Novotna M, Paz Soldán MM, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M, Kantarci OH.

Neurology. 2015 Aug 25;85(8):722-9. doi: 10.1212/WNL.0000000000001856. Epub 2015 Jul 24. Erratum in: Neurology. 2015 Oct 13;85(15):1355.

4.

No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.

Becker M, Latarche C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F.

BMC Neurol. 2015 May 13;15:79. doi: 10.1186/s12883-015-0330-4.

5.

The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.

Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S.

Prog Neurobiol. 2015 Apr;127-128:1-22. doi: 10.1016/j.pneurobio.2015.02.003. Epub 2015 Mar 21. Review.

6.

Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.

Najafi B, Ghaderi H, Jafari M, Najafi S, Ahmad Kiadaliri A.

Glob J Health Sci. 2014 Oct 9;7(2):139-47. doi: 10.5539/gjhs.v7n2p139.

7.

MS Prevalence and Patients' Characteristics in the District of Braga, Portugal.

Figueiredo J, Silva Â, Cerqueira JJ, Fonseca J, Pereira PA.

Neurol Res Int. 2015;2015:895163. doi: 10.1155/2015/895163. Epub 2015 Jan 8.

8.

Relapses and disability accumulation in progressive multiple sclerosis.

Paz Soldán MM, Novotna M, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Weinshenker BG, Rodriguez M, Kantarci OH.

Neurology. 2015 Jan 6;84(1):81-8. doi: 10.1212/WNL.0000000000001094. Epub 2014 Nov 14.

9.

Environmental factors and multiple sclerosis severity: a descriptive study.

Mandia D, Ferraro OE, Nosari G, Montomoli C, Zardini E, Bergamaschi R.

Int J Environ Res Public Health. 2014 Jun 19;11(6):6417-32. doi: 10.3390/ijerph110606417.

10.
11.

The role of neurotrophins in multiple sclerosis-pathological and clinical implications.

Kalinowska-Lyszczarz A, Losy J.

Int J Mol Sci. 2012 Oct 22;13(10):13713-25. doi: 10.3390/ijms131013713. Review.

12.

Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.

Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH.

Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26.

13.

Age and disability accumulation in multiple sclerosis.

Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA.

Neurology. 2011 Sep 27;77(13):1246-52. doi: 10.1212/WNL.0b013e318230a17d. Epub 2011 Sep 14.

14.

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC.

Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9.

15.
16.

High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.

Nash RA, Bowen JD, McSweeney PA, Pavletic SZ, Maravilla KR, Park MS, Storek J, Sullivan KM, Al-Omaishi J, Corboy JR, DiPersio J, Georges GE, Gooley TA, Holmberg LA, LeMaistre CF, Ryan K, Openshaw H, Sunderhaus J, Storb R, Zunt J, Kraft GH.

Blood. 2003 Oct 1;102(7):2364-72. Epub 2003 May 22.

17.

Multiple sclerosis in Finland: incidence trends and differences in relapsing remitting and primary progressive disease courses.

Sumelahti ML, Tienari PJ, Hakama M, Wikström J.

J Neurol Neurosurg Psychiatry. 2003 Jan;74(1):25-8.

18.

Changes in gait and fatigue from morning to afternoon in people with multiple sclerosis.

Morris ME, Cantwell C, Vowels L, Dodd K.

J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):361-5.

19.

Prevalence of multiple sclerosis in the L'Aquila district, central Italy.

Totaro R, Marini C, Cialfi A, Giunta M, Carolei A.

J Neurol Neurosurg Psychiatry. 2000 Mar;68(3):349-52.

Supplemental Content

Support Center